Peak oxygen consumption as a predictor of death in patients with heart failure receiving β-blockers

Circulation

Volumn 111, Issue 18, 2005, Pages 2313-2318

  O'Neill, James O ^a   Young, James B ^a   Pothier, Claire E ^a   Lauer, Michael S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenergic beta antagonists; Exercise; Heart failure; Prognosis; Ventricular dysfunction, left

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXERCISE; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; DEATH; EXERCISE TEST; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; MIDDLE AGED; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STROKE VOLUME;

EID: 18444365325     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000164270.72123.18     Document Type: Article

References (31)

1. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-786.
2. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1995;92:3593-3612.
3. Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med. 1998;129:286-293.
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
6. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
7. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004;10:15-20.
8. Robbins M, Francis G, Pashkow FJ, Snader CE, Hoercher K, Young JB, Lauer MS. Ventilatory and heart rate responses to exercise: better predictors of heart failure mortality than peak oxygen consumption. Circulation. 1999;100:2411-2417.
9. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol. 1986;60:2020-2027.
10. Wasserman K. Breathing during exercise. N Engl J Med. 1978;298:780-785.
11. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA. 2000;284:1392-1398.
12. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation. 1983;68:951-960.
13. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106:793-800.
14. Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM. Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol. 1985;121:754-766.
15. Newman TB, Brown AN. Use of commercial record linkage software and vital statistics to identify patient deaths. J Am Med Inform Assoc. 1997;4:233-237.
16. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
17. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543-2546.
18. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis. 1984;129:S49-S55.
19. Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2001.
20. Francis GS. Determinants of prognosis in patients with heart failure. J Heart Lung Transplant. 1994;13:S113-S116.
21. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI5-VI16.
22. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
23. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551.
24. Gullestad L, Manhenke C, Aarsland T, Skardal R, Fagertun H, Wikstrand J, Kjekshus J. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. Eur J Heart Fail. 2001;3:463-468.
25. Weber KT, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation. 1982;65:1213-1223.
26. Francis GS, Rector TS. Maximal exercise tolerance as a therapeutic end point in heart failure - are we relying on the right measure? Am J Cardiol. 1994;73:304-306.
27. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, Haass M. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol. 2002;39:1615-1622.
28. Peterson LR, Schechtman KB, Ewald GA, Geltman EM, de las Fuentes L, Meyer T, Krekeler P, Moore ML, Rogers JG. Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. J Heart Lung Transplant. 2003;22:1141-1148.
29. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol. 1999;34:618-620.
30. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet. 1997;349:662-663.
31. Lloyd-Jones DM, Martin DO, Larson MG, Levy D. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998;129:1020-1026.